ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global MarketsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global MarketsFREMONT, CA - February 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, announces a new strategy with its joint venture partner, BioLite Japan. The parties aim to accelerate the growth of Japan's biotechnology industry by facilitating access to Taiwan’s capital market and leveraging cutting-edge AI resources for advanced development.
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesLicensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl’s Plans
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025FREEMONT, CALIFORNIA - February 20, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, central nervous system (CNS), and oncology/hematology, today announced its expectation to receive $7M in cash licensing income in 2025, stemming from existing global licensing agreements the Company and one of its subsidiaries signed in 2023. The company is also highlighting significant progress in its botanical drug development pipeline and its plans to leverage land assets for future development.
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 BillionFREMONT, CA - February 12, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focusing on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced its participation in BioLive’s (formerly known as TT Life) Health Talk Event, marking a significant milestone in the company’s growth and its role in advancing innovative healthcare solutions by penetrating a new market in Asia. The event showcased BioKey’s Maitake BLEX 404 Dietary Supplement, a groundbreaking therapy created for cancer combination treatment and to enhance immunity, in an effort to help improve the quality of life for cancer patients.
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion MarketFREMONT, CA - January 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is proud to announce the advancements in its innovative treatments for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD), highlighting the promising results achieved through rigorous clinical research and development.
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementFREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to announce that Nasdaq has granted the Company an additional 180-day grace period, until July 7, 2025, to regain compliance with the Nasdaq Capital Market’s minimum $1.0 bid price per share requirement.
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related ProductsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AISearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing DealsFREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporation’s securities to which the parties impute a value of $6 per share based on an internal valuation1 and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Company’s other licensees. In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively.2 The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
